JP2018517892A - 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル - Google Patents

結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル Download PDF

Info

Publication number
JP2018517892A
JP2018517892A JP2017552968A JP2017552968A JP2018517892A JP 2018517892 A JP2018517892 A JP 2018517892A JP 2017552968 A JP2017552968 A JP 2017552968A JP 2017552968 A JP2017552968 A JP 2017552968A JP 2018517892 A JP2018517892 A JP 2018517892A
Authority
JP
Japan
Prior art keywords
panel
proteins
individual
biomarker
catd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017552968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517892A5 (cg-RX-API-DMAC7.html
Inventor
ブルーム，ジョン
ジョーンズ，ジェフリー
ベンズ，ライアン
カオ，アティット
クロナー，リサ
ディロン，ロスリン
ヨウ，ジア
ウィルコックス，ブルース
Original Assignee
アプライド プロテオミクス，インク．
アプライド プロテオミクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプライド プロテオミクス，インク．, アプライド プロテオミクス，インク． filed Critical アプライド プロテオミクス，インク．
Publication of JP2018517892A publication Critical patent/JP2018517892A/ja
Publication of JP2018517892A5 publication Critical patent/JP2018517892A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G01N33/57535—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/575—
    • G01N33/57585—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
JP2017552968A 2015-04-10 2016-04-08 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル Pending JP2018517892A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562146158P 2015-04-10 2015-04-10
US62/146,158 2015-04-10
US201562160560P 2015-05-12 2015-05-12
US62/160,560 2015-05-12
US201562165846P 2015-05-22 2015-05-22
US62/165,846 2015-05-22
US201562196889P 2015-07-24 2015-07-24
US62/196,889 2015-07-24
US201562239771P 2015-10-09 2015-10-09
US62/239,771 2015-10-09
PCT/US2016/026773 WO2016164815A1 (en) 2015-04-10 2016-04-08 Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Publications (2)

Publication Number Publication Date
JP2018517892A true JP2018517892A (ja) 2018-07-05
JP2018517892A5 JP2018517892A5 (cg-RX-API-DMAC7.html) 2019-05-16

Family

ID=55795201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017552968A Pending JP2018517892A (ja) 2015-04-10 2016-04-08 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル

Country Status (7)

Country Link
US (3) US9689874B2 (cg-RX-API-DMAC7.html)
EP (1) EP3281016A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018517892A (cg-RX-API-DMAC7.html)
CA (1) CA2982169A1 (cg-RX-API-DMAC7.html)
GB (1) GB2545361B (cg-RX-API-DMAC7.html)
HK (1) HK1255533A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016164815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
KR101937531B1 (ko) * 2016-09-28 2019-01-10 국립암센터 대장암 진단 장치와 대장암 진단 정보 제공 방법
US20180100858A1 (en) 2016-10-07 2018-04-12 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
US11062792B2 (en) 2017-07-18 2021-07-13 Analytics For Life Inc. Discovering genomes to use in machine learning techniques
US11139048B2 (en) 2017-07-18 2021-10-05 Analytics For Life Inc. Discovering novel features to use in machine learning techniques, such as machine learning techniques for diagnosing medical conditions
EP3721232A1 (en) * 2017-12-05 2020-10-14 DiscernDx, Inc. Robust panels of colorectal cancer biomarkers
JP7102509B2 (ja) * 2018-04-04 2022-07-19 富士フイルム株式会社 医療文書作成支援装置、医療文書作成支援方法、及び医療文書作成支援プログラム
JP7431760B2 (ja) * 2018-06-30 2024-02-15 ２０／２０ ジェネシステムズ，インク 癌分類子モデル、機械学習システム、および使用方法
KR102745118B1 (ko) * 2018-07-05 2024-12-23 이디피 바이오테크 코퍼레이션 마커 검출용 키트 및 방법
US11011276B2 (en) * 2018-07-09 2021-05-18 Chang Gung Memorial Hospital, Linkou Method for establishing computer-aided data interpretation model for immune diseases by immunomarkers and visualization
EP4038391A1 (en) * 2019-10-01 2022-08-10 AC Immune SA Micro-radiobinding assays for ligand screening
US20210349017A1 (en) * 2020-05-08 2021-11-11 Caci, Inc. - Federal Systems and methods for detection of biological agents using infrared spectroscopy
EP4295307A4 (en) * 2021-02-16 2024-12-18 Verily Life Sciences LLC Systems and methods for biomarker detection in digitized pathology samples
US20250266162A1 (en) * 2021-05-13 2025-08-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis
WO2024208824A1 (en) * 2023-04-03 2024-10-10 Oncodiag Methods for the diagnosis and surveillance of cancer
CN118983105A (zh) * 2024-06-24 2024-11-19 浙江省肿瘤医院 一种用于高级别浆液性卵巢癌晚期患者无复发生存的预测模型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506917A (ja) * 2007-12-10 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 結腸直腸癌のためのマーカーパネル
JP2013511728A (ja) * 2009-11-20 2013-04-04 ユニバーシティ オブ ルイスビル リサーチ ファンデーション，インコーポレイテッド 癌のバイオマーカー
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4517289A (en) 1982-08-18 1985-05-14 Brigham And Women's Hospital Monoclonal antibodies for human tissue cross-matching
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5790761A (en) 1992-12-11 1998-08-04 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
AU6350894A (en) 1993-03-05 1994-09-26 Clifford W. Schweinfest Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas
US7229770B1 (en) 1998-10-01 2007-06-12 The Regents Of The University Of California YKL-40 as a marker and prognostic indicator for cancers
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US5800347A (en) 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
NO954667D0 (no) 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
US5983211A (en) 1996-01-24 1999-11-09 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
US6242212B1 (en) 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6303372B1 (en) 1998-06-12 2001-10-16 Chiron Corporation cDNA molecule encoding human CIF130
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
EP1179092A2 (en) 1999-01-10 2002-02-13 Exact Sciences Corporation Methods of detecting colorectal disease by conduction an assay to detect a mutation in a bat-26 locus
US7153700B1 (en) 1999-03-26 2006-12-26 Dana-Farber Cancer Institute, Inc. Methods and compositions for diagnosing and predicting the behavior of cancer
NZ515311A (en) 1999-04-09 2002-11-26 Rigshospitalet Mass screening and highly specific early identification of colorectal or metastatic breast cancer by measuring TIMP-1 tissue inhibitor
US20010041365A1 (en) 2000-01-10 2001-11-15 Michael Laposata Methods for monitoring alcohol consumption
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US7301016B2 (en) 2000-03-07 2007-11-27 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
US7577683B2 (en) 2000-06-08 2009-08-18 Ingenuity Systems, Inc. Methods for the construction and maintenance of a knowledge representation system
US6531283B1 (en) 2000-06-20 2003-03-11 Molecular Staging, Inc. Protein expression profiling
AU2001280639A1 (en) 2000-07-18 2002-01-30 Millennium Pharmaceuticals, Inc. 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
US6706506B2 (en) 2000-07-24 2004-03-16 Cornell Research Foundation, Inc. Detection of epithelial cell cancers and precancerous conditions
WO2002074960A2 (en) 2000-11-08 2002-09-26 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
US7312086B2 (en) 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
IL158003A0 (en) 2001-03-23 2004-03-28 Yeda Res & Dev Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer
CN1526025A (zh) 2001-05-16 2004-09-01 ��˹��ŵ�� 作为预后和治疗靶标的乳腺癌中表达的基因
US7031846B2 (en) 2001-08-16 2006-04-18 Affymetrix, Inc. Method, system, and computer software for the presentation and storage of analysis results
DE60239690D1 (de) 2001-09-07 2011-05-19 Univ Johns Hopkins Med Sezernierte und zelloberflächengene, die in gutartigen und bösartigen kolorektaltumoren exprimiert werden
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
US20030186248A1 (en) 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
WO2003097872A2 (en) 2002-05-21 2003-11-27 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
US20050153382A1 (en) 2002-06-06 2005-07-14 Chengdu Kuachang Science And Technology Co., Ltd. Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
DE102004037860A1 (de) 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
PT1761779E (pt) 2004-08-13 2008-02-01 Indivumed Gmbh Utilização de transtirretina como um biomarcador de adenoma colorrectal; método de detecção e sistema de teste
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
WO2006047483A2 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
WO2006094149A2 (en) 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
WO2006102526A2 (en) 2005-03-22 2006-09-28 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Identification of biomarkers by serum protein profiling
EP1920071B1 (en) 2005-07-29 2018-12-26 Siemens Healthcare Diagnostics Inc. Neoplastic disease-related methods, kits, systems and databases
CN101263391A (zh) 2005-09-12 2008-09-10 菲诺梅诺米发现公司 通过测量维生素e-相关的代谢物诊断结肠直肠癌和卵巢癌的方法
JP5038311B2 (ja) 2005-09-12 2012-10-03 フェノメノーム ディスカバリーズ インク ビタミンｅ関連代謝産物の測定による、結腸直腸癌及び卵巣癌の診断方法
WO2007036025A1 (en) 2005-09-27 2007-04-05 University Of Saskatchewan Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosls
US7662580B2 (en) 2005-11-10 2010-02-16 Aurelium Biopharma Inc. Tissue diagnostics for breast cancer
GB0524190D0 (en) 2005-11-28 2006-01-04 Helse Stavanger Hf Method
ES2277785B1 (es) 2005-12-21 2008-06-16 Oryzon Genomics, S.A. Metodo de analisis de expresion diferencial en cancer colorectal.
US20090035801A1 (en) 2005-12-27 2009-02-05 Power3 Medical Products, Inc. Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
EP2412821B1 (en) 2006-01-11 2014-09-17 Genomic Health, Inc. AREG as a gene expression marker for colorectal cancer prognosis
WO2007090125A2 (en) 2006-01-30 2007-08-09 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
WO2007127002A2 (en) 2006-03-31 2007-11-08 Cell Signaling Technology, Inc. Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors
CA2657691A1 (en) 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
CA2708006A1 (en) 2006-12-08 2008-06-19 The Johns Hopkins University Cancer chemoprevention strategy based on loss of imprinting of igf2
EP2450702A3 (en) 2007-01-26 2012-07-25 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2008116178A2 (en) 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
US8697350B2 (en) 2007-06-04 2014-04-15 Diagnoplex Biomarker combinations for colorectal cancer
US8883440B2 (en) 2007-07-26 2014-11-11 Nancy M. Lee Method to predict or diagnose a gastrointestinal disorder or disease
DE102007034993A1 (de) 2007-07-26 2009-01-29 Hanna Diehl Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs
WO2009040782A2 (en) 2007-09-28 2009-04-02 Royal College Of Surgeons In Ireland A method of assessing colorectal cancer status in an individual
CN101868729B (zh) 2007-11-20 2013-07-17 霍夫曼-拉罗奇有限公司 利用标记物组合钙防卫蛋白和血红蛋白/触珠蛋白复合物从粪便样品评价结肠直肠癌的方法
KR101058753B1 (ko) 2007-11-22 2011-08-24 한국생명공학연구원 대장암 마커로서의 ｅｓｍ－１ 유전자 및 이를 이용한대장암의 진단 및 치료에의 용도
DK2223115T3 (da) 2007-12-10 2011-12-12 Hoffmann La Roche Seprase som markør for cancer
EP2249644A4 (en) 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc PICOPLATIN AND AMRUBICIN USEFUL IN THE TREATMENT OF LUNG CANCER
AU2009213671A1 (en) 2008-02-11 2009-08-20 Hadasit Medical Research Services & Development Limited Colon cancer associated transcript 1 (CCAT1) as a cancer marker
WO2009107170A1 (ja) 2008-02-29 2009-09-03 学校法人日本大学 抗ｃｒｐ抗体及びその利用
EP2255017A1 (en) 2008-03-18 2010-12-01 Epigenomics AG A method for optimizing and validating an assay for determining the presence or absence of a medical condition
EP2259797A2 (en) 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
EP2868754A1 (en) 2008-04-10 2015-05-06 Genenews Corporation Method for determining a probability of colorectal cancer in a subject
JP2011521215A (ja) 2008-05-14 2011-07-21 エーテーハー チューリヒ 前立腺癌の診断及び治療のためのバイオマーカー及び薬剤標的発見法、並びにそれを用いて決定されるバイオマーカーアッセイ
US8697370B2 (en) 2008-05-23 2014-04-15 Pronota N.V. Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof
CN102165075A (zh) 2008-07-18 2011-08-24 奥洁克公司 用于检测和治疗结肠直肠癌的组合物
EP2169077A1 (en) 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
US20100204299A1 (en) 2009-02-11 2010-08-12 Daniel Regnier C-cbl and antagonists thereof for the treatment and diagnosis of cancer
EP2398918B1 (en) 2009-02-20 2018-06-20 Onconome, Inc. Methods for diagnosis and prognosis of colorectal cancer
CA2753119A1 (en) 2009-02-24 2010-09-02 F. Hoffmann-La Roche Ag Use of s-erbb-3 as a marker for cancer
AU2010306593B2 (en) 2009-10-15 2015-09-10 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring inflammatory disease activity
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
CA2790416C (en) 2010-03-26 2017-05-23 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
US10119959B2 (en) 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
GB201012590D0 (en) 2010-07-27 2010-09-08 Queen Mary & Westfield College Methods for diagnosing cancer
US8389684B2 (en) 2010-09-13 2013-03-05 Tsinghua University Tumor biomarker
EP2668503B1 (en) 2011-01-28 2015-06-24 F.Hoffmann-La Roche Ag Combinatorial biomarkers for clinical applications in lung cancer patient management
CA2827894A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CA2845568A1 (en) 2011-08-19 2013-02-28 Myriad Genetics, Inc. Gene signatures for lung cancer prognosis and therapy selection
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US20150141273A1 (en) * 2012-04-26 2015-05-21 Stichting Vu-Vumc Biomarkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506917A (ja) * 2007-12-10 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 結腸直腸癌のためのマーカーパネル
JP2013511728A (ja) * 2009-11-20 2013-04-04 ユニバーシティ オブ ルイスビル リサーチ ファンデーション，インコーポレイテッド 癌のバイオマーカー
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
COUTSOFTIDES ET AL: "Colonoscopy and the Management of Polyps Containing Invasive Carcinoma", ANN SURG, vol. 188, no. 5, JPN6020002747, 1978, pages 638 - 641, ISSN: 0004201082 *
ETZIONI ET AL: "THE CASE FOR EARLYDETECTION", NATURE REVIEWS, vol. 3, JPN6020002742, 2003, pages 1 - 10, ISSN: 0004201080 *
FERRONI ET AL: "PROGNOSTIC VALUE SOLUBLE P-SELECTIN LEVELS IN COLORECTAL CANCER", INT J CANCER, vol. 111, JPN6020002734, 2004, pages 404 - 408, ISSN: 0004201076 *
KOPETZ ET AL: "Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Can", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 2, JPN6020002755, 2010, pages 453 - 459, ISSN: 0004201085 *
LEE ET AL: "Macrophage Migration Inhibitory Factor May Be Used as an Early Diagnostic Marker in Colorectal Carci", AM J CLIN PATHOL, vol. 129, JPN6020002735, 2008, pages 772 - 779, ISSN: 0004201077 *
MERCER: "Use of Multiple Markers to Enhance Clinical Utility", IMMUNOL SER, vol. 53, JPN6020002745, 1990, pages 39 - 54, ISSN: 0004201081 *
MINICOZZI ET AL: "Disease presentation, treatment and survival for Italian colorectal cancer patients: a EUROCARE high", EUR J PUBLIC HEALTH, vol. 24, no. 1, JPN6020002749, 2014, pages 98 - 100, ISSN: 0004201083 *
PINCZOWER ET AL: "CHARACTERISATION OF THE TUMOUR-ASSOCIATED CARBOHYDRATE EPITOPE RECOGNISED BY MONOCLONAL ANTIBODY 4D3", INT J CANCER, vol. 66, JPN6020002739, 1996, pages 636 - 644, ISSN: 0004201079 *
PINCZOWER: "NOMOCLONAL ANTIBODY 4D3 DETECTS SMALL INTESTINAL MUCIN ANTIGEN (SIMA)-GLYCOPROTEIN IN THE SERUM OF P", INT J CANCER, vol. 54, JPN6020002737, 1993, pages 391 - 396, ISSN: 0004201078 *
THORSEN ET AL: "Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplas", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 11, no. 253, JPN6020002752, 2013, pages 1 - 13, ISSN: 0004201084 *
WILD ET AL: "A Combination of Serum Markers for the Early Detection of Colorectal Cancer", CLIN CANCER RES, vol. 16, no. 24, JPN6020002731, 2010, pages 6111 - 6121, ISSN: 0004201074 *
XIE ET AL: "Novel Proteomic Strategy Reveal Combined α1 Antitrypsin and Cathepsin D as Biomarkers for Colorecta", JOURNAL OF PROTEOME RESEARCH, vol. 9, JPN6020002733, 2010, pages 4701 - 4709, ISSN: 0004201075 *

Also Published As

Publication number Publication date
GB201703773D0 (en) 2017-04-26
US9689874B2 (en) 2017-06-27
EP3281016A1 (en) 2018-02-14
CA2982169A1 (en) 2016-10-13
US20170370937A1 (en) 2017-12-28
US20160299144A1 (en) 2016-10-13
WO2016164815A1 (en) 2016-10-13
HK1255533A1 (zh) 2019-08-16
US20190257835A1 (en) 2019-08-22
GB2545361A (en) 2017-06-14
GB2545361B (en) 2018-01-24

Similar Documents

Publication Publication Date Title
US9689874B2 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
CN104969071B (zh) 用于评估结肠肿瘤的存在或风险的方法
JP7311417B2 (ja) 肺癌の検出および処置のための方法
Wadsworth et al. Identification of patients with head and neck cancer using serum protein profiles
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20170176441A1 (en) Protein biomarker profiles for detecting colorectal tumors
HK1248316A1 (en) Methods of assessing colorectal health of an individual
JP2017530356A (ja) 心血管系のリスクイベントの予測及びその使用
JP2025522362A (ja) マルチオミクス評価
KR20240004546A (ko) 결장직장암에 대한 바이오마커
WO2025145100A1 (en) Multi-omics assessment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210322